BridgeBio Pharma (NASDAQ:BBIO) Director Jennifer Cook Sells 90,240 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Jennifer Cook sold 90,240 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $66.62, for a total transaction of $6,011,788.80. Following the transaction, the director owned 6,589 shares in the company, valued at $438,959.18. This represents a 93.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Stock Performance

BridgeBio Pharma stock opened at $67.39 on Thursday. The firm has a market cap of $13.20 billion, a price-to-earnings ratio of -18.02 and a beta of 0.97. BridgeBio Pharma, Inc. has a 1 year low of $39.65 and a 1 year high of $84.94. The firm’s 50 day moving average price is $69.89 and its two-hundred day moving average price is $72.04.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The business had revenue of $194.52 million for the quarter, compared to analysts’ expectations of $178.07 million. The business’s revenue was up 66.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.88) EPS. As a group, equities analysts predict that BridgeBio Pharma, Inc. will post -2.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Weiss Ratings restated a “sell (d)” rating on shares of BridgeBio Pharma in a research report on Friday, May 15th. Mizuho decreased their price target on shares of BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating on the stock in a research report on Tuesday. HC Wainwright restated a “buy” rating and issued a $110.00 price target on shares of BridgeBio Pharma in a research report on Thursday, May 28th. Leerink Partners restated an “outperform” rating and issued a $98.00 price target on shares of BridgeBio Pharma in a research report on Thursday, March 12th. Finally, Raymond James Financial lowered shares of BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 26th. Twenty-two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $91.05.

Hedge Funds Weigh In On BridgeBio Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in BridgeBio Pharma by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 16,832,059 shares of the company’s stock worth $874,257,000 after purchasing an additional 347,074 shares during the period. Janus Henderson Group PLC boosted its stake in BridgeBio Pharma by 19.8% in the 1st quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock worth $978,608,000 after purchasing an additional 2,178,556 shares during the period. Farallon Capital Management LLC boosted its stake in BridgeBio Pharma by 9.8% in the 4th quarter. Farallon Capital Management LLC now owns 8,998,463 shares of the company’s stock worth $688,292,000 after purchasing an additional 806,463 shares during the period. Aisling Capital Management LP boosted its stake in shares of BridgeBio Pharma by 0.4% during the 3rd quarter. Aisling Capital Management LP now owns 6,089,611 shares of the company’s stock valued at $316,294,000 after buying an additional 21,486 shares during the period. Finally, Invesco Ltd. boosted its stake in shares of BridgeBio Pharma by 23.0% during the 4th quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock valued at $369,547,000 after buying an additional 902,648 shares during the period. Institutional investors and hedge funds own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.